Nash and his colleagues came up with the idea based on similar treatment that blood cancer patients receive. "Because many of the immune cells are being killed off, there's an immune reset following the treatment," Nash said. Doctors harvest and preserve the patient's stem cells before treatment, and re-implant them following chemotherapy. This new therapy seeks to reset the immune system by killing it off using high-dose chemotherapy, then restarting it using the patient's own blood stem cells. Over time, as the damage mounts, patients become physically weak, have problems with coordination and balance, and suffer from thinking and memory problems. People with the more common form, called relapsing-remitting MS, have attacks of worsening neurologic function followed by partial or complete recovery periods (remissions). In multiple sclerosis, the body's immune system for some unknown reason attacks the nervous system, in particular targeting the insulating sheath that covers the nerve fibers, according to the U.S. "We still need to perform a randomized clinical trial, but we're all pretty impressed so far, in terms of what we've seen." "I think we all think of this as a viable therapy," Nash said. Richard Nash of the Colorado Blood Cancer Institute at Presbyterian/St. And nine in 10 experienced no progression or relapse in their MS, said lead author Dr. 29, 2014 (HealthDay News) - An experimental therapy that kills off and then "resets" the immune system has given three years of remission to a small group of multiple sclerosis patients, researchers say.Ībout eight in 10 patients given this treatment had no new adverse events after three years. Contact Emily Viles-Monari with questions.MONDAY, Dec. If you are a neuroimmunology and/or MS fellow, register here. View the ACTRIMS Didactic Lecture Faculty Disclosures here. If you are unable to watch the webinars live, you may watch them on-demand and still receive a CME certificate. A survey will be sent to all participants after each webinar to claim credit for that specific webinar. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Interstate Postgraduate Medical Association designations this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. This webinar series has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. Integrate cross-disciplinary tools to manage symptomatic concerns for MS and other neuroimmune diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |